Preparing for DSCSA Interoperability
Phase II of DSCSA requires interoperable systems for the electronic tracking of product through the supply chain. Is pharma prepared? Learn what stakeholders need to know and do know to prepare for 2023.
Our Most-Read Insights of 2018
A collection of AmerisourceBergen's top insights from 2018, including commercialization considerations for novel therapies, emerging trends in retail and specialty pharmacy and best practices for managing inventory in the specialty practice.
Pharmacy Systemness: The Powerful Potential of Consolidated Distribution
A look at how health systems can stem the tide of rising pharmacy costs with a consolidated distribution model.
Pharmacy Systemness, Part Three: Why a Consolidated Distribution Model Makes Sense for Health Systems
The primary benefits of consolidated distribution, and what health systems need to know before getting started.
Rethink: Channel Strategy for Oral Oncolytics
How manufacturers can benefit from provider-led care coordination to improve patient outcomes.
Commercially Available Unit Dose Products: Enhancing Access to Treatments and Promoting Pharmacy Efficiency
While suppliers are making fewer pre-packaged unit dose treatments available, health system pharmacies still have options for acquiring them. Learn which is best.
How Product Commercialization Impacts Patients
How do channel strategy decisions impact providers and patients—and how can you ensure a patient-centric commercialization strategy? Our strategic global sourcing experts share insights on how customers respond to channel strategy decisions.
Pharmacy Systemness, Part Two: Consolidation Offers a Better Distribution Method for Health Systems
How health systems can gain the benefits of a centralized distribution model without the excessive capital investment.
A New Approach to Channel Strategy for Oncology Therapies
How is manufacturer thinking around channel strategy changing for oral oncolytics?
Pharmacy Systemness, Part One: The Case for Consolidated Distribution
Can health systems implement self-distribution without the capital investment in freestanding warehouse space? Yes.
Full-line vs. Specialty Distribution
What manufacturers need to know about how distribution impacts access.
How do manufacturers' distribution decisions ultimately impact patients? What long- and short-term disruption do direct models present? AmerisourceBergen experts offer perspective on the unintended consequences of channel strategy decisions.
Leadership in Specialty
Our strategic global sourcing experts share how AmerisourceBergen's leadership in specialty distribution influences the way we partner with manufacturers.
An Inside Look at the Customer Experience
Our experts share what customers wish manufacturers knew about product access.
The Downstream Impact of Channel Strategy Decisions
What manufacturers need to know about the customer experience.
Four Questions That Will Move Pharma Forward
Key themes from ThinkLive 2017, AmerisourceBergen's annual manufacturer summit.
How Wholesalers Have Evolved in Recent Years
How pharmaceutical wholesalers have evolved in recent years.
Improving Customer Experience and Driving Long-Term Value for Manufacturers
Rich Tremonte on the current healthcare landscape, the role of the wholesaler and how the new organizational structure at AmerisourceBergen brings out the best in both.
Learn the unintended consequences of channel strategy decisions and the impact on patients and providers.
Practical Data in an Insights-driven World
How should manufacturers be using distribution data to uncover insights and manage access?
Five Good Reasons to Use a Single Distributor
The advantages of buying from one source.
How prepackaged unit dose medications can increase safety and efficiency while lowering risk and costs for America’s hospitals